Association of cellular immunity with severity of COVID-19 from the perspective of antigen-specific memory T cell responses and cross-reactivity

Fujii, Shin-ichiro; Yamasaki, Satoru; Iyoda, Tomonori; Shimizu, Kanako

doi:10.1186/s41232-022-00239-1

Table 1 Immunodominant peptides and associated HLA class I

From: Association of cellular immunity with severity of COVID-19 from the perspective of antigen-specific memory T cell responses and cross-reactivity

Protein	Start	End	Length	Peptide	HLA Class I	Source
S	865	873	9	LTDEMIAQY	A^*01:01	ref. [42], ref. [43]
M	171	179	9	ATSRTLSYY	A^*01:01	ref. [44], ref. [43]
nsp3	819	828	10	TTDPSFLGRY	A^*01:01	ref. [40], ref. [44], ref. [45]
nsp3	503	511	9	PTDNYITTY	A^*01:01	ref. [44], ref. [43]
nsp3	818	828	11	HTTDPSFLGRY	A^*01:01	ref. [46], ref. [45]
nsp5	174	182	9	GTDLEGNFY	A^*01:01	ref. [44], ref. [43]
nsp12	738	746	9	DTDFVNEFY	A^*01:01	ref. [44], ref. [42], ref. [43]
ORF3a	207	215	9	FTSDYYQLY	A^*01:01	ref. [44], ref. [41], ref. [42], ref. [45]
S	269	277	9	YLQPRTFLL	A^*02:01	ref. [44], ref. [38], ref. [47], ref. [45], ref. [43]
S	1000	1008	9	RLQSLQTYV	A^*02:01	ref. [47], ref. [45], ref. [43]
S	424	433	10	KLPDDFTGCV	A^*02:01	ref. [43], ref. [48]
nsp3	1514	1522	9	ILFTRFFYV	A^*02:01	ref. [42], ref. [45], ref. [43]
nsp4	337	344	8	FLPGVYSV	A^*02:01	ref. [45], ref. [43]
nsp7	27	35	9	KLWAQCVQL	A^*02:01	ref. [44], ref. [43]
nsp8	152	160	9	ALWEIQQVV	A^*02:01	ref. [44], ref. [43]
ORF3a	139	147	9	LLYDANYFL	A^*02:01	ref. [44], ref. [38], ref. [43]
ORF3a	107	115	9	YLYALVYFL	A^*02:01	ref. [42], ref. [43]
N	361	369	9	KTFPPTEPK	A^03:01 A^11:01	ref. [44], ref. [41], ref. [45]
N	134	143	10	ATEGALNTPK	A^*11:01	ref. [40, 49], ref. [44], ref. [45]
S	448	456	9	NYNYLYRLF	A^*24:02	ref. [50], ref. [45], ref. [43]
S	1208	1216	9	QYIKWPWYI	A^*24:02	ref. [51], ref. [40], ref. [44], ref. [45], re [43].
nsp3	1349	1357	9	NYMPYFFTL	A^*24:02	ref. [45], ref. [43]
nsp13	397	405	9	VYIGDPAQL	A^*24:02	ref. [40], ref. [44]
ORF3a	112	120	9	VYFLQSINF	A^*24:02	ref. [40], ref. [44], ref. [43]
N	105	113	9	SPRWYFYYL	B^*07:02	ref. [44], ref. [41], ref. [42], ref. [45], ref. [43], ref. [52]
N	257	265	9	KPRQKRTAT	B^*07:02	ref. [42], ref. [45]
nsp13	592	600	9	IPRRNVATL	B^*07:02	ref. [44], ref. [42]
S	919	927	9	NQKLIANQF	B^*15:01	ref. [38]
N	9	17	9	QRNAPRITF	B^*27:05	ref. [40], ref. [41]
N	322	331	10	MEVTPSGTWL	B^*40:01	ref. [40], ref. [41], ref. [42], ref. [45], ref. [53]

Back to article page

ISSN: 1880-8190

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com

Inflammation and Regeneration

Contact us